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BACKGROUND: The health-promoting and disease-limiting abilities 
of resveratrol, a natural polyphenol, has led to considerable interest 
in understanding the mechanisms of its therapeutic actions. The 
polyphenolic rings of resveratrol enable it to react with and detoxify 
otherwise injurious oxidants. Whilst the protective actions of resveratrol 
are commonly ascribed to its antioxidant activity, here we show that this is 
a misconception.
METHODS: The ability of resveratrol to oxidize cGMP-dependent PKG1α 
(protein kinase 1α) was assessed in isolated rat aortic smooth muscle 
cells, and the mechanism of action of this polyphenol was characterized 
using in vitro experiments, mass spectrometry and electron paramagnetic 
resonance. The blood pressure of wild-type and C42S knock-in mice was 
assessed using implanted telemetry probes. Mice were made hypertensive 
by administration of angiotensin II via osmotic mini-pumps and blood 
pressure monitored during 15 days of feeding with chow diet containing 
vehicle or resveratrol.
RESULTS: Oxidation of the phenolic rings of resveratrol paradoxically 
leads to oxidative modification of proteins, explained by formation of a 
reactive quinone that oxidizes the thiolate side chain of cysteine residues; 
events that were enhanced in cells under oxidative stress. Consistent 
with these observations and its ability to induce vasodilation, resveratrol 
induced oxidative activation of PKG1α and lowered blood pressure in 
hypertensive wild-type mice, but not C42S PKG1α knock-in mice that are 
resistant to disulfide activation.
CONCLUSIONS: Resveratrol mediates lowering of blood pressure 
by paradoxically inducing protein oxidation, especially during times 
of oxidative stress, a mechanism that may be a common feature of 
antioxidant molecules.
© 2019 The Authors. Circulation is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution License, 
which permits use, distribution, and 
reproduction in any medium, provided 
that the original work is properly cited.
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Resveratrol is a non-flavonoid polyphenolic com-pound that was first identified in extracts from the white hellebore Veratrum grandiflorum.1 After its 
discovery resveratrol has been characterized as a phyto-
alexin also found in the skin of several fruits, with the most 
notable being grapes.2 Studies exploring the biological 
effects of resveratrol have provided compelling evidence 
for its ability to extend life-span in numerous species, in-
cluding yeast, worms, flies and mice.3 In addition, resve-
ratrol exhibits beneficial effects in diverse animal disease 
models. This includes the prevention of cardiovascular 
and neurological diseases, cancer, metabolic syndrome, 
as well as promoting bone and eye health.4 The ability 
of resveratrol to promote health and prevent disease has 
predominantly been attributed to its antioxidant activity 
and to some extent direct target interaction. The most 
notable direct target of resveratrol being NAD-dependent 
protein SIRT1 (deacetylase sirtuin-1), which despite being 
highly publicized, is in fact likely an artefactual result of an 
in vitro activity assay used in the original study.4–7 Despite 
this setback genuine direct targets of resveratrol have 
been subsequently identified and include cAMP phos-
phodiesterases and tyrosyl transfer-RNA synthetase.8,9 
Although these targets of resveratrol are known, the bio-
logical mechanisms that mediate this polyphenol’s protec-
tive signaling are yet to be fully elucidated. Here we pro-
vide a novel thiol-dependent mechanism that mediates, 
at least in part, the beneficial actions of resveratrol. This 
mechanism involves the oxidation of thiols that includes 
a new biological target, which mediates the vasodilatory 
properties of this polyphenol, namely PKG1α (protein ki-
nase 1α). This ability of resveratrol to modify cysteine thi-
ols was catalyzed by superoxide, the formation of which 
is often causatively associated with disease.10–13 There-
fore, this thiol-mediated activity of resveratrol is likely to 
be restricted to the pro-oxidative environment of diseased 
tissues, thus mediating beneficial signaling at the site of 
injury. Consequently, this study provides novel insight as 
to how resveratrol promotes health and limits disease, as 
well as highlighting the ability of antioxidants to mediate 
protective signaling by counterintuitively inducing thiol 
oxidation.
METHODS
An extended methods section is available in the online-only 
Data Supplement. The data, analytical methods, and study 
materials will be made available to other researchers for pur-
poses of reproducing the results or replicating the procedure 
and are available by contacting the corresponding author.
Measuring PKG1α Disulfide Dimerization
1.15 μg/μl of recombinant PKG1α (Merck Millipore) was 
reduced for 30 minutes by addition of 2 mmol/L dithiothrei-
tol. After reduction PKG1α was diluted to 24.5 ng/μl in 100 
mmol/L Tris-HCl pH 7.4. Diluted PKG1α was then exposed to 
100 μmol/L resveratrol (Sigma) or DMSO. After 30 minutes 
incubation at room temperature reactions were terminated 
by the addition of sample buffer (50 mmol/L Tris-HCl buffer 
pH 6.8, 2% SDS, 10% glycerol, 0.005% bromophenol blue) 
containing 100 mmol/L maleimide to prevent further PKG1α 
oxidation. Samples were then resolved on SDS-PAGE gels and 
immunoblotted for PKG1α (Enzo Life Sciences).
Cell Culture
Rat aortic smooth muscle cells (SMC) were cultured in 
Dulbecco’s Modified Eagle’s medium supplemented with 1% 
Penicillin-Streptomycin and 10% fetal bovine serum. Human 
primary vascular SMC were cultured in medium 199 supple-
mented with 1% penicillin-streptomycin and 20% fetal bovine 
serum. SMC were maintained at 37oC in a 20%O2/5%CO2 
incubator and grown on 12-well culture plates until 90% con-
fluent (approximately 0.3 x 106) before experimental treatment. 
In some experiments, cells were maintained at 5%O2/5%CO2. 
Cultured SMC were treated with freshly prepared resveratrol or 
resveratrol pre-exposed to 25 minutes of UV irradiation (Blak-
Ray B-100AP high intensity UV lamp). In some experiments 
SMC were treated with 10 μmol/L menadione sodium bisulfite 
(Sigma) alone or with 100 μmol/L resveratrol. In all experiments 
SMC were lysed 25 minutes after treatment in sample buffer 
containing 100 mmol/L maleimide. To assess PKG1α intramo-
lecular disulfide formation, SMC were pretreated with resvera-
trol for 15 minutes then a further 10 minutes with 200 μmol/L 
1-nitrosocyclohexyl acetate.
Electron Paramagnetic Resonance
Resveratrol (20 mmol/L) or equivalent volume of DMSO in PBS 
was supplemented with 17 mmol/L 2-methyl-2-nitrosopropane 
Clinical Perspective
What Is New?
• In our study we explain how resveratrol may medi-
ate its numerous beneficial effects, including low-
ering of blood pressure, by direct thiol oxidation.
• The natural polyphenol resveratrol can counterin-
tuitively induce direct protein oxidation, a process 
that is enhanced under pro-oxidative conditions 
associated with disease.
• The oxidation of cGMP-dependent protein kinase 
1α (PKG1α) by resveratrol lowers blood pressure in 
hypertensive mice.
What Are the Clinical Implications?
• Our study using a murine model of hypertension 
demonstrates how blood pressure can be lowered 
using resveratrol.
• Targeting cysteine 42 on PKG1α may provide a 
new class of therapeutic that can lower blood pres-
sure in hypertensive patients.
• Identifying additional proteins modified by resve-
ratrol may provide new targets for therapy to treat 
cardiovascular disease.
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in the presence of absence of tyrosinase. The formation of 
2-methyl-2-nitrosopropane adducts was analyzed using 
electron paramagnetic resonance (Magnettech Miniscope 
MS2000 spectrometer) after 160 minutes incubation at room 
temperature.
Animals
All procedures were performed in accordance with the 
Home Office Guidance on the Operation of the Animals 
(Scientific Procedures) Act 1986 in the United Kingdom. 
Experiments were approved by the King’s College London 
Animal Welfare and Ethical Review Body. Mice constitu-
tively expressing PKGIα Cys42Ser were generated on 
a pure C57BL/6 background by TaconicArtemis (Köln, 
Germany) as previously described.14 Wild-type or littermate 
C42S PKG1α knock-in (KI) male mice were used at 14–15 
weeks of age.
Isolated Mesenteric Vessel Preparation
Mesenteric arteries from wild-type or C42S PKG1α KI mice 
were isolated, cleaned of adipose and connective tissue 
then mounted in a Danish Myo Technology tension myo-
graph system. Mounted vessels submerged in Krebs solu-
tion were stretched to their optimal pre-tension using the 
tension myograph normalization module at 37ºC containing 
95% O2:5% CO2. The vasotone of each vessel to increasing 
concentrations of resveratrol was measured after wake-up 
with KCl (60 mmol/L) and after constriction to U46619 (0.1 
μmol/L).
Angiotensin II–Induced Hypertension and 
Resveratrol Feeding
Mice were randomized and data analysis was blinded to the 
operator. No animals were excluded after the randomiza-
tion. Groups were age and weight matched. After baseline 
recordings (4 days) mice were again anesthetized (2% iso-
flurane in 0.5 L of oxygen/minute) and subjected to subcu-
taneous implantation of osmotic minipumps (model 1002; 
Alzet) for delivery of angiotensin II (Sigma) at an infusion 
rate of 1.1 mg/kg/day. Perioperative analgesia (buprenor-
phine, 0.1 mg per kg of body weight; Abbot Laboratories) 
was provided, and the wellbeing of mice monitored daily. 
Resveratrol was delivered orally (~320mg/kg) and to miti-
gate stress or risk of dislodging the telemetric probe cath-
eter, it was provided suspended in water and set in gelatin 
flavored with sodium saccharin and mixed with chow. Food 
consumption was monitored daily, which on average did 
not vary between genotypes. At the end of the feeding 
study, mice were euthanized and mesenteries isolated for 
analysis.
Statistical Analysis
Results are presented as mean±SE. Differences between 2 
groups were assessed using a 2-tailed unpaired Student t test 
or for multiple comparisons an ANOVA followed by Tukey 
post hoc analysis. All datasets had a normal distribution, as 
confirmed using the Shapiro-Wilk normality test. Results were 
considered significant with P values ≤ 0.05.
RESULTS
Resveratrol alone induced a significant increase in re-
combinant PKG1α disulfide formation, observed on 
immunoblots and by a loss in reduced vicinal thiols de-
tected by a decrease in dibromobimane fluorescence 
(Figure 1A and 1B). Consistent with resveratrol inducing 
PKG1α oxidation, the catalytic activity of the kinase was 
also enhanced independently of cGMP (Figure 1C).15
The ability of resveratrol to induce PKG1α oxidation 
was substantiated in primary cultured rat aortic SMC 
and human vascular SMC exposed to this polyphenol. 
Treatment of SMC with resveratrol induced PKG1α 
oxidation, which was significantly enhanced when res-
veratrol was pre-exposed to ultraviolet (UV) light (Fig-
ure 2A and Figure IA through IC in the online-only Data 
Supplement). The oxidation of PKG1α by resveratrol 
induced a Cys42-dependent intermolecular disulfide, 
but not an intramolecular bond between Cys117 and 
Cys195 (Figure ID in the online-only Data Supplement). 
In addition, resveratrol did not prevent the intramo-
lecular disulfide between Cys117 and Cys195 that was 
induced by the HNO donor,16 1-nitrosocyclohexyl ac-
etate. Therefore, the oxidation of PKG1 by resveratrol 
is likely to be selective for cysteine 42. As well as induc-
ing PKG1α oxidation, resveratrol also caused disulfide 
dimerization of the regulatory I-α subunit of cAMP-
dependent protein kinase (PKARI; Figure IE and IF in 
the online-only Data Supplement).17 Therefore, protein 
oxidation is likely a generic mechanism for mediating 
resveratrol-induced signaling. The ability of resveratrol 
to induce protein oxidation through a direct thiol ad-
duction mechanism was assessed using reverse phase 
liquid chromatography. The modification of cysteine 
by resveratrol was observed after UV light exposure, as 
indicated by detection of additional, nascent products 
(Figure 2B). To provide further insight to the mechanism 
by which resveratrol adducts thiols, the presence of it 
trans or cis isomers was assessed based on their dif-
ferential fluorescence properties, as determined using 
commercial standards (Figure IIA in the online-only Data 
Supplement). The addition of resveratrol to an aque-
ous solution led to its spontaneous partial isomeriza-
tion from the trans to the cis form (Figure 2C and 2D 
and Figure IIA and IIB in the online-only Data Supple-
ment). The cis isomer generated after addition of aque-
ous solution, was lost over time and correlated with 
increased end-product formation measured at 450 nm. 
This is consistent with the spontaneous conversion of 
cis-resveratrol to the end-product form, with this pro-
cess catalyzed by UV light. In addition, the spontaneous 
isomerization of resveratrol and slow accumulation of 
end-product upon addition of aqueous PBS did not oc-
cur in DMSO. The colored end-product formed in aque-
ous solution was consistent with resveratrol dimeriza-
tion.18,19 This was supported by its similarity in color and 
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absorbance to viniferin, with the end-product also likely 
comprising of other various oligomers (Figure IIC in the 
online-only Data Supplement). These changes in the 
chemical composition of the polyphenol upon addition 
to aqueous solution was substantiated using additional 
commercial sources of trans-resveratrol (Figure III in the 
online-only Data Supplement). For each commercial 
source of trans-resveratrol tested, partial isomerization 
to the cis form occurred spontaneously upon addition 
to aqueous PBS. This cis isomer was then lost with time, 
which correlated with increased formation of an end-
product that absorbed at 450 nm.
Upon addition to aqueous solution, an intermedi-
ate form of resveratrol with thiol reactivity was likely 
generated, as end-product formation was inhibited by 
co-incubation with L-cysteine (Figure 3A). Furthermore, 
resveratrol end-product formation and loss of the cis 
isoform was catalyzed by superoxide generated by 
SOTS-1 (Figure  3B). Therefore, it is conceivable that 
oxidation of resveratrol may catalyze formation of a 
thiol-reactive intermediate, which in isolation resolves 
to form the end-product. The ability of superoxide to 
enhance formation of a thiol reactive resveratrol inter-
mediate was further supported by experiments using 
menadione. Although menadione can induce PKG1α 
oxidation in SMC alone, through elevated oxidant for-
mation, this was substantially enhanced in the presence 
of resveratrol (Figure 3C).
The ability of resveratrol to mediate protein oxida-
tion and undergo dimerization is consistent with redox 
cycling between a semiquinone (phenoxyl radical) and 
quinone form, which is also attributed to its antioxidant 
Figure 1. Resveratrol induces direct PKG1α oxidation and activation.  
A, Recombinant PKG1α undergoes disulfide dimerization when exposed to resveratrol (n=4–5). B, Resveratrol prevents modification of vicinal thiols on PKG1α 
by dibromobimane (dBBr), which emulated air oxidation (n=6). C, Resveratrol induces cGMP-independent stimulation of PKG1α activity consistent with oxidative 
activation (n=4). ***P<0.005. All data are presented as mean±SE. and analyzed using unpaired Student t test (A) or 1-way ANOVA followed by Tukey.
Figure 2. Exposure of resveratrol to UV irradiation enhances its ability to mediate thiol oxidation.  
A, PKG1α oxidation in SMC is significantly enhanced when resveratrol is pre-exposed to UV irradiation (n=6). B, UV irradiation of resveratrol converts it from the 
trans to the cis form as previously described. However, in the presence of cysteine new products are formed (*) consistent with cysteine adducted by resveratrol. 
C, When placed into aqueous solution resveratrol is slowly converted into a colored end-product that is catalyzed by initial UV irradiation. The initial detection of 
trans, cis and end-product forms of resveratrol is shown in each graph. D, The addition of resveratrol to aqueous solution immediately induces partial isomeriza-
tion of the trans to cis form. This cis form is then time-dependently lost with formation of an end-product. ***P<0.005. All data are presented as mean±SE. and 
analyzed using 1-way ANOVA followed by Tukey (A). 
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activity.18–22 This is also consistent with increased end-
product formation when resveratrol is deprotonated to 
the phenolate anion form under basic pH, which will 
catalyze semiquinone formation (Figure IV in the on-
line-only Data Supplement). The generation of superox-
ide consistent with redox cycling of resveratrol between 
a semiquinone and quinone form, was detected by the 
reduction of nitro-blue tetrazolium, which was attenu-
ated by superoxide dismutase (Figure 4A). Spontaneous 
formation of a resveratrol semiquinone upon addition 
of aqueous solution, was further substantiated using 
electron paramagnetic resonance. Incubation of res-
veratrol with 2-methyl-2-nitrosopropane generated a 
composite electron paramagnetic resonance spectrum 
whose main components comprised a 3-line light-in-
duced (aN = 16.5 G) and a 6-line spectrum (aN = 13.5 G; 
aH = 16.9 G) characteristic of a carbon centered adduct 
(Figure 4B). As tyrosinase catalyzes quinone formation 
by 2 electron oxidation this will limit semiquinone for-
mation. Therefore, as the novel 2-methyl-2-nitrosopro-
pane adduct was absent in samples when also supple-
mented with tyrosinase, this substantiates formation of 
a resveratrol semiquinone. The redox cycling of resve-
ratrol to a quinone form may underlie its capacity to 
modify cysteine, as it would confer an ability to adduct 
to thiols through a Michael addition reaction across 
its α,β-unsaturated carbonyl. This was investigated by 
analyzing the formation of cysteine resveratrol adducts 
using mass spectrometry. Here the incubation of cyste-
ine with resveratrol led to formation of products con-
sistent with thiol covalently bound to the polyphenol, 
which can be observed in the mass spectrum with or 
without the addition of an ammonium ion adduct (Fig-
ure 4C). The formation of resveratrol covalently bound 
to cysteine was further substantiated, as additional 
products were absent in samples containing cysteine or 
resveratrol alone (Figure VA and VB in the online-only 
Data Supplement). In addition, the formation of an am-
monium adduct of cysteine bound resveratrol (m/z 348) 
was confirmed by tandem mass spectrometry analysis. 
Fragmentation of the product at m/z 366 generated a 
dominant ion at m/z 348 (Figure 4D), which after fur-
ther fragmentation matched the profile for the m/z 348 
ion for cysteine bound resveratrol (Figure 4E and 4F). 
Here the addition of resveratrol also induced a relative 
increase in the abundance of cystine, thus further sup-
porting the ability of this polyphenol to directly induce 
disulfide formation (Figure VC in the online-only Data 
Supplement). This capacity of resveratrol to catalyze a 
disulfide between 2 cysteine molecules is consistent 
with a direct reaction of the polyphenol with PKG1α 
Cys42 that induces intermolecular disulfide formation. 
As resveratrol also directly catalyzed the S-glutathiola-
tion of recombinant glyceraldehyde 3-phosphate dehy-
drogenase, this further corroborates the ability of this 
polyphenol to generically induce disulfide formation 
(Figure VIA in the online-only Data Supplement).
The ability of resveratrol to modify cysteine through 
a reactive intermediate was further investigated, by se-
lectively catalyzing quinone formation using the phenol 
oxidase enzyme tyrosinase. The 2-electron oxidation 
of resveratrol by tyrosinase led to rapid end-product 
Figure 3. Superoxide catalyzes resveratrol end-product formation and its ability to oxidize PKG1α.  
A, Cysteine attenuates the conversion of resveratrol to its end-product consistent with a thiol-reactive intermediate. B, The addition of the superoxide donor SOTS-
1 to resveratrol rapidly enhances end-product formation. C, The oxidation of PKG1α mediated by menadione is substantially enhanced by addition of resveratrol 
(n=6). ***P<0.005. All data are presented as mean±SE. and analyzed using 2-way ANOVA followed by Sidak post hoc test (C). 
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formation and loss of the cis form, consistent with en-
hanced dimerization (Figure 5A). In addition, the qui-
none form of resveratrol generated by tyrosinase was 
highly reactive and led to loss of free thiols in BSA, 
detected by a decrease in either monobromobimane 
fluorescence or biotin-maleimide labeling (Figure  5B 
and 5C). The ability of a resveratrol quinone to mod-
ify proteins was further substantiated in cell lysates by 
detection of the polyphenol conjugated to proteins on 
SDS-PAGE gels irradiated with UV (Figure VIB in the 
online-only Data Supplement). This modification of 
proteins by resveratrol was dramatically enhanced by 
addition of tyrosinase, consistent with enhanced thiol 
reactivity of the quinone form (Figure 5D).
The ability of resveratrol to induce PKG1α oxidation 
mediated to some extent its vasodilatory action in iso-
lated constricted mesenteric vessels (Figure  6A). Here 
resveratrol-induced vasorelaxation was impaired in ves-
sels from C42S PKG1α KI mice when compared with 
littermate wild-types. Consistent with direct oxidative 
activation of vascular smooth muscle cell PKG1α, the 
relaxation to resveratrol in L-NAME-treated or endothe-
lium denuded vessels was comparable to control tissue 
(Figure VIIA in the online-only Data Supplement). The 
ability of resveratrol to mediate vasodilation and thus 
lower blood pressure was further assessed in angiotensin 
II–induced hypertensive mice monitored telemetrically. 
Here oral feeding of resveratrol significantly attenu-
ated angiotensin II–induced hypertension in wild-type 
but not C42S PKG1α KI mice (Figure 6B through 6D). 
However, feeding of resveratrol did not impact on heart 
rate or mouse activity (Figure 6E and Figure VIIB in the 
online-only Data Supplement). In mice fed resveratrol, 
plasma serum albumin was modified by this polyphenol, 
which was detected by mass spectrometry (Figure VIIC 
and VIID in the online-only Data Supplement). This find-
ing corroborates the capacity of resveratrol to directly 
modify protein thiols in mice that consume it. Resvera-
trol-induced protein oxidation likely explains its ability 
to lower blood pressure in hypertensive mice, with en-
hanced PKG1α disulfide dimerization being a principal 
causative mechanism. This was substantiated by disul-
fide dimerization of PKG1α in the mesenteric vessels of 
resveratrol fed mice, which was significantly enhanced 
in wild-type animals also administered angiotensin II 
(Figure 6F). As enhanced PKG1α oxidation mediated by 
resveratrol was only observed in wild-type hypertensive 
mice, it is likely this process is driven by oxidation of the 
polyphenol, mediated by angiotensin II–induced super-
oxide formation.23 Indeed, as resveratrol was found to 
be largely stable in the food preparation, this further 
supports the likelihood of polyphenol oxidation in vivo, 
which in turn will induce PKG1α disulfide dimerization 
(Figure VIIE in the online-only Data Supplement).
Figure 4. Resveratrol is converted into a semiquinone when placed into aqueous solution and can directly modify cysteine.  
A, The conversion of reduced nitroblue tetrazolium (NBT) to its formazan form is enhanced in a time and concentration-dependent manner by resveratrol, which 
is attenuated by superoxide dismutase (SOD), thus consistent with superoxide formation. B, In aqueous solution resveratrol is converted to a semiquinone radical 
that modifies 2-methyl-2-nitrosopropane (MNP), which is absent in samples supplemented with tyrosinase. C, Product spectra from positive-ion electrospray mass 
spectrometry analysis of cysteine adducts after incubation with resveratrol. Here products with a mass consistent with cysteine covalent bound to resveratrol alone 
and with an ammonium ion adduct were detected. D, Fragmentation of product ion m/z 366 from C. E, Fragmentation of product m/z 348 from D. F, Fragmenta-
tion of product ion m/z 348 from C.
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DISCUSSION
The medicinal benefits of resveratrol have been exten-
sively characterized in animal models of health and dis-
ease, however it has proven difficult to translate these 
findings to the treatment of human disease. Although 
there have been some promising outcomes in the treat-
ment of Alzheimer disease, which suggest it can modu-
late neuro-inflammation and induce adaptive immuni-
ty.24 Despite resveratrol having so far failed to translate 
to a clinical use, which is largely attributed to its poor 
bioavailability, the beneficial effects in animal models, 
including extension in life-span, warrants a greater un-
derstanding of its biological activity.25,26 Certainly, im-
proved insight into the mechanistic basis for the actions 
of resveratrol, could provide new therapeutic strategies 
with improved potency in humans.
In this study, we examined the potential for resve-
ratrol to mediate at least in part its beneficial effects 
through oxidative signaling. The rational being pheno-
lic antioxidants are innately, and often overlooked, pro-
oxidants due their ability to redox cycle.27 Indeed, in the 
case of resveratrol a pro-oxidative activity has already 
been attributed.28,29 Resveratrol alone induces oxidative 
DNA damage that is enhanced by transition metal ions 
including copper.30 Indeed, this ability of resveratrol to 
induce oxidative DNA damage has been implicated as 
a possible mechanism for its anticancer activity.31 The 
polyphenols pro-oxidative activity is likely through reac-
tive species formation upon electron transfer from res-
veratrol to oxygen, leading to conversion of its phenolic 
hydroquinone to a semiquinone.
Here we found resveratrol alone was enough to in-
duce oxidation and subsequent activation of recombi-
nant PKG1α. This was consistent with auto-oxidation of 
resveratrol in solution, thus generating a thiol-reactive 
intermediate or reactive oxygen species that would cat-
alyze disulfide formation. Consistent with the auto-oxi-
dation of resveratrol we observed a slow chemical shift 
upon its addition to aqueous solution, characterized by 
increased coloration and absorbance at 450 nm. This 
chemical change was likely explained by formation of 
the resveratrol dimer viniferin through semiquinone 
attack of a second resveratrol molecule or free radical 
Figure 5. A resveratrol semiquinone intermediate modifies protein thiols.  
A, Addition of tyrosinase (Tyr) enhances end-product formation visualized after 5 minutes incubation. B, Resveratrol modifies reduced thiols on bovine serum 
albumin in a concentration-dependent manner that is enhanced by tyrosinase, assessed by a loss in conjugated monobromobimane fluorescence. C, The loss of 
free thiols on BSA after exposure to resveratrol was substantially enhanced by tyrosinase, as observed by a decrease in biotin-maleimide conjugation. D, Modifica-
tion of proteins by resveratrol within cell lysate is substantially enhanced by tyrosinase, observed after SDS-PAGE separation followed by exposure of proteins to UV 
irradiation.
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coupling.18,19 This observation resonates with a recent 
study where resveratrol dimers and tetramers were syn-
thesized using a resveratrol radical.32 As with this study 
it is likely that the end-products we observed also com-
promises a mixture of resveratrol derivatives because of 
divergent cyclisation pathways. The formation of super-
oxide upon addition of resveratrol to aqueous solution 
was again consistent with a semiquinone intermedi-
ate that redox cycles between its hydroquinone form. 
Certainly, a semiquinone is also a likely intermediate 
in the reaction of resveratrol with superoxide, which is 
considered crucial to its well-described antioxidant ac-
tivity. This has been described through two potential 
mechanisms, one consisting of hydrogen-atom transfer 
and the other through a single electron transfer reac-
tion.20–22 Studies assessing the antioxidant activity of 
resveratrol using density functional theory, determined 
that because of resonance the 4’-OH group has greater 
reactivity than those on the opposing ring in the 3- or 
5- positions.33 In addition, the antioxidant activity of 
resveratrol is attributed to formation of a semiquinone 
in which the unpaired electron is mainly distributed on 
Figure 6. PKG1α oxidation mediates the vasodilatory action of resveratrol.  
A, Resveratrol induced vasodilation of constricted mesenteric vessels that was significantly impaired in those isolated from C42S KI mice (n=5–6). B, Feeding 
hypertensive mice with resveratrol significantly lowers mean arterial pressure (MAP) in wild-type (WT) but not C42S PKG1α KI mice (n=5–6). C and D, Feeding of 
resveratrol lowers systolic (SP) and diastolic pressure (DP) to a greater extent in hypertensive wild-type compared with C42S PKG1α KI mice (n=5–6). E, Feeding 
of resveratrol does not impact on heart rate (HR; n=5–6). F, Feeding resveratrol increases PKG1α oxidation in angiotensin II (AngII) hypersensitive wild-type mice 
(n=5–6). *P<0.05. All data are presented as mean±SE and analyzed using 2-way ANOVA followed by Sidak post hoc test. 
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the O-atom at the para position. The importance of the 
4’-OH group in mediating the antioxidant activity of 
resveratrol is further supported by quantum-chemical 
calculations, in which this group was shown to be a 
strong proton donor and capable of forming a semi-
quinone.34
The ability of UV exposure to enhance resveratrol-
mediated cysteine thiol oxidation is likely through in-
creased formation of its quinone form. Indeed, this 
is consistent with enhanced end-product formation 
through attack of a second resveratrol molecule by a 
semiquinone intermediate. In addition, the spontane-
ous formation of a semiquinone intermediate of res-
veratrol upon addition to aqueous solution seems to 
require isomerization of the trans to cis form. This is 
evident from a time-dependent loss of the cis isomer 
with accumulation of its end-product. It is conceivable 
that this could be explained by enhanced sensitivity of 
the cis form to auto-oxidation. Indeed, this could also 
explain why UV light enhances the thiol reactivity of 
resveratrol, by increasing isomerization to the cis form, 
which is then subsequently converted to a quinone. The 
oxidation of resveratrol is also enhanced by superoxide 
formation as the donor SOTS-1 rapidly increased end-
product formation. This is consistent with its hydrogen-
atom transfer or single electron transfer reaction.20–22 
These findings suggest that under biological conditions 
where superoxide formation is elevated, as occurs in 
many prevalent diseases, resveratrol will be converted 
to a thiol-reactive quinone form. Certainly, this would 
be predicted as the catalytic conversion of resveratrol 
to a quinone form using tyrosinase, leads to enhanced 
protein modification. The modification of proteins by 
resveratrol under pro-oxidizing conditions may underlie 
its ability to mediate protective signaling. Indeed, this 
ability of resveratrol to modify protein thiols is consis-
tent with the adduction of glutathione within the hu-
man liver microsome.35 This modification of glutathi-
one by resveratrol, detected using mass spectrometry, 
was consistent with a thiol reactive quinone form. The 
chemistry required for modification of glutathione by 
resveratrol will not differ from that of a protein thiol. 
Therefore, it is perhaps unsurprising that modification 
of proteins by resveratrol was observed and was en-
hanced by tyrosinase. Here we were able to detect cys-
teine modified by resveratrol using mass spectrometry, 
and proteins modified by resveratrol using UV irradia-
tion, which provides a novel strategy that can be uti-
lized to further investigate this new mode of signaling. 
The modification of proteins by resveratrol may in part 
underlie its biological effects, which will be potentiated 
under pro-oxidizing conditions associated with preva-
lent diseases, because of enhanced redox cycling and 
quinone formation. Therefore, the numerous beneficial 
actions of resveratrol attributed to its antioxidant ac-
tivity is likely a misconception, as this is contradicted 
by the formation of an oxidized thiol reactive interme-
diate that promotes oxidative signaling. As the thiol 
reactivity of a resveratrol quinone will be constrained 
by the structural and electrochemical properties sur-
rounding susceptible cysteine residues, this will limit 
the targets that undergo this modification. Therefore, 
in diseased tissue it is likely resveratrol converts a non-
selective oxidant into a discriminatory form that medi-
ates beneficial oxidative signaling to promote health. 
Furthermore, the well-documented ability of resveratrol 
to prevent disease by lowering oxidative stress is also 
likely a misconception. This is because oxidative stress 
is normally based on the measure of a select oxidant 
(eg, superoxide) or post-translational modification (eg, 
Figure 7. Overview of thiol-dependent mechanism of resveratrol action. The addition of trans-resveratrol to aqueous solution induces spontaneous isomeri-
zation to the cis form. Once formed cis-resveratrol auto-oxidizes to a semiquinone that is catalyzed by superoxide. The unstable semiquinone intermediate transi-
tions to a quinone form or dimerizes through a free radical coupling reaction. A resveratrol quinone generated through polyphenol oxidation has the propensity to 
modify protein cysteine thiols through a Michael addition reaction.
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protein carbonylation), whereas protein modification by 
quinones is not normally assessed. This counterintuitive 
role of resveratrol means that despite its ability to lower 
common markers of oxidative stress, it is likely protein 
oxidation by this polyphenol is enhanced under disease 
conditions. The proposed mechanism of thiol adduc-
tion by resveratrol is shown in Figure 7.
It is likely that resveratrol modifies multiple targets 
in addition to PKG1α, with the rational possibility that 
these may also mediate its beneficial effects. Consistent 
with this idea, numerous proteins were modified by res-
veratrol in a tyrosinase-catalyzed reaction as observed 
under UV irradiation. In addition, PKARI also underwent 
disulfide dimerization in SMC treated with resveratrol, 
identifying this kinase as another novel target of this 
polyphenol. Based on these findings, it is also conceiv-
able that some of the known processes regulated by 
resveratrol could be attributed to its ability to modify 
protein cysteine thiols. This may include its ability to 
regulate NAD(P)H oxidase activity, or eNOS (endothe-
lial nitric oxide synthase) phosphorylation, an event 
that improves endothelial function in type 2 diabetic 
mice.36 Also, protein thiol modification could contribute 
to prevention of stretch-induced high-mobility group 
box 1 release by resveratrol, which protects against 
lung endothelial barrier dysfunction.37 As this protec-
tive mechanism is dependent on Nrf2 (nuclear factor 
erythroid 2-related factor 2), it is conceivable that res-
veratrol could modify cysteines on KEAP1 (kelch-like 
ECH-associated protein 1), thus enabling the stabiliza-
tion of Nrf2. This may be anticipated, as KEAP1 is well 
known to generically react with low molecular weight 
electrophiles, such as sulforaphane.38 This mechanism 
may also underlie the ability of resveratrol to induce ex-
pression of antioxidant genes, through thiol-dependent 
activation of Nrf2.
The disulfide dimerization of PKG1α may be in-
duced by resveratrol through a polyphenol conjugated 
thiol intermediate. Alternatively, disulfide formation 
may be mediated by 1 electron oxidation of cysteine 
42 of PKG1α to a thiyl radical by a semiquinone res-
veratrol intermediate. The formation of a thiyl radical 
then leads to generation of a disulfide through reac-
tion with an adjacent reduced thiol, and the donation 
of an electron to oxygen.39 However, superoxide gener-
ated upon resveratrol auto-oxidation could also medi-
ate disulfide formation through its conversion to H2O2, 
by spontaneous dismutation or catalyzed by cellular 
superoxide dismutase.40 This is consistent with previ-
ous studies showing H2O2 can induce PKG1α disulfide 
dimerization and activation.15,41 The contribution of 
each process in resveratrol-mediated PKG1α disulfide 
dimerization is difficult to assess, as it is not possible to 
isolate and identify the intermediates involved. Despite 
this limitation we have identified PKG1α as a bona fide 
novel target of resveratrol, in which the polyphenol 
promotes activation of the kinase by inducing disulfide 
dimerization. This mechanism of oxidative PKG1α acti-
vation mediates in part the biological activity of resve-
ratrol. In constricted mesenteries, the ability of resvera-
trol to mediate vasorelaxation was partially impaired in 
those expressing a redox-dead C42S form of PKG1α. 
This ability of resveratrol to relax mesenteric vessels 
was also found to be endothelium-independent, thus 
further supporting the potential role of vascular SMC 
PKG1α oxidation in mediating the biological actions of 
this polyphenol. Although only a minor difference in 
relaxation between wild-type or C42S KI vessels was 
observed, these were healthy vessels and therefore 
resveratrol redox cycling may be limited. It is therefore 
conceivable that in diseased vessels where oxidant for-
mation is elevated that the relaxation to resveratrol 
would be potentiated by its ability to further enhance 
PKG1α oxidation. This is consistent with experiments 
using the oxidant generator menadione, where its abil-
ity to oxidize PKG1α was substantially enhanced in 
cells co-treated with resveratrol. Based on these find-
ings, we predicted that resveratrol would lower blood 
pressure in angiotensin II hypertensive mice by enhanc-
ing the oxidation of PKG1α. Here the rationale was 
superoxide formation associated with the pathological 
effects of angiotensin II would potentiate redox cycling 
of resveratrol,23 which would then couple to enhanced 
PKG1α oxidation to lower blood pressure. Consistent 
with previous studies, we found that feeding resvera-
trol effectively lowered blood pressure in hypertensive 
wild-type mice.42,43 Importantly and in accordance with 
our hypothesis, we found that this lowering of blood 
pressure, mediated by resveratrol, was absent in C42S 
PKG1α KI mice. The role of PKG1α disulfide dimeriza-
tion in mediating the blood pressure lowering action 
of resveratrol was further substantiated in mesenteric 
vessels. An increase in PKG1α oxidation mediated by 
resveratrol was observed only in wild-type hypertensive 
mouse mesenteric vessels, therefore it is likely this pro-
cess is driven by oxidation of the polyphenol, mediated 
by angiotensin II–induced superoxide formation.23 This 
ability of resveratrol to lower blood pressure may also 
be mediated by oxidative modulation of other proteins 
in addition to PKG1α. This includes cysteine thiols on 
PKARI, which were also found to undergo polyphenol-
induced oxidation.44
A limitation of this study is the lack of patient data, 
which is important to establish that animal findings 
can be translated to humans. However, as resveratrol 
induced PKG1α oxidation in human vascular SMC, it 
is anticipated that our findings will be translatable to 
the treatment of human hypertension. This is also con-
sistent with H2O2-dependent dilation of human coro-
nary arterioles being mediated by the disulfide dimer-
ization of PKG1α.45 Therefore, based on our findings 
we predict that under disease conditions with altered 
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reactive oxygen species bioavailability or pH, the abil-
ity of resveratrol to induce protein oxidation may be 
enhanced, thus potentiating beneficial signaling. It is 
also important to bear in mind that as well as protein 
oxidation, resveratrol through a similar mechanism 
may also induce DNA damage,28,30 which could have a 
deleterious effect that should be carefully assessed be-
fore conducting human studies. Together, our findings 
provide a novel mechanism that underlies the ability of 
resveratrol to lower blood pressure, which is through 
oxidation of C42 on PKG1α. This observation is also 
consistent with our previous work where we identified 
a thiol-reactive drug termed G1, which likewise lowers 
blood pressure through oxidation of C42 on PKG1α.46 
Therefore, based on our observations and the numer-
ous health benefits of resveratrol, protein cysteine thiols 
may represent promising targets for future drug devel-
opment.
In summary, here we describe a new paradigm in an-
tioxidant signaling as resveratrol can paradoxically me-
diate its biological actions through protein oxidation, 
which is because of its ability to redox cycle. A new 
target of this novel mode of signaling is C42 on PKG1α, 
which when oxidized by resveratrol lowers blood pres-
sure in hypertensive animals.
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